ViewRay Company Profile (NASDAQ:VRAY)

About ViewRay (NASDAQ:VRAY)

ViewRay logoViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company's software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:VRAY
  • CUSIP: N/A
  • Web:
  • Market Cap: $296.67 million
  • Outstanding Shares: 57,383,000
Average Prices:
  • 50 Day Moving Avg: $6.42
  • 200 Day Moving Avg: $6.10
  • 52 Week Range: $2.64 - $10.39
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -12.02
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $18.01 million
  • Price / Sales: 16.47
  • Book Value: ($0.48) per share
  • Price / Book: -10.77
  • EBIDTA: ($41,220,000.00)
  • Net Margins: -362.22%
  • Return on Assets: -82.10%
  • Debt-to-Equity Ratio: -1.64%
  • Current Ratio: 1.79%
  • Quick Ratio: 1.56%
  • Average Volume: 672,127 shs.
  • Beta: -0.17
  • Short Ratio: 9.29
Frequently Asked Questions for ViewRay (NASDAQ:VRAY)

What is ViewRay's stock symbol?

ViewRay trades on the NASDAQ under the ticker symbol "VRAY."

How were ViewRay's earnings last quarter?

ViewRay, Inc. (NASDAQ:VRAY) posted its quarterly earnings results on Monday, May, 15th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.02. The company earned $1.23 million during the quarter, compared to analyst estimates of $0.52 million. The company's quarterly revenue was down 77.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.35) earnings per share. View ViewRay's Earnings History.

Where is ViewRay's stock going? Where will ViewRay's stock price be in 2017?

4 analysts have issued 12 month price targets for ViewRay's shares. Their forecasts range from $7.00 to $11.00. On average, they anticipate ViewRay's stock price to reach $9.50 in the next twelve months. View Analyst Ratings for ViewRay.

What are analysts saying about ViewRay stock?

Here are some recent quotes from research analysts about ViewRay stock:

  • 1. Northland Securities analysts commented, "We are maintaining our FY17 & FY18 numbers, and our PT & ratings remain the same. Key Points Perhaps the most interesting takeaway from the call was the announcement of a multi-institutional trial on unresectable pancreatic cancer using MRIdian. It is our understanding that this trial will include both MRIdian Cobalt & LINAC (as they become available); will include a hard endpoint like survival, and possibly" intraop dose titration and impact on outcomes. As a reminder, most patients with pancreatic cancer will die within 1 – 2 years, with median survival @ 1-year. Hence, it is certainly possible that ViewRay could provide survival endpoints for such a trial in late 2018 / early 2019. This obviously is predicated on the trial design, sample size, inclusion criteria, and whether this will be randomized or not. The ideal design would obviously be to include a comparative arm with another RT machine (like the TruBeam) & compare to MRIdian. Finally, how outcomes will be influenced with the use of Cobalt vs. LINAC will also be interesting to note, although it might be hard to draw any statistical conclusions given small sample size." (5/16/2017)
  • 2. Aegis analysts commented, "We are assuming coverage of VRAY with a Buy rating and $11 PT. We believe the MRI-guided LINAC is a game-changer in radiation oncology, with real-time imaging improving dosimetry and reducing the toxicity to patients. The combination improves functionality and expands the use of stereotactic body radiation therapy (SBRT), and physicians believe the system can expand the total treatable tumors by at least 20%." (5/16/2017)
  • 3. BTIG Research analysts commented, "While we admit the higher price per system may impact how many hospitals will ultimately adopt, we feel the early adopters who are less price sensitive will drive strong initial orders and the stock over the next few years."If properly marketed, patients will learn about live imaging and, we believe, seek out centers with its availability. We are not calling for ISRG like success this early but could envision a similar hospital arms race," (9/14/2016)

Who are some of ViewRay's key competitors?

When did ViewRay IPO?

(VRAY) raised $52 million in an initial public offering on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

How do I buy ViewRay stock?

Shares of ViewRay can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ViewRay's stock price today?

One share of ViewRay stock can currently be purchased for approximately $5.17.

MarketBeat Community Rating for ViewRay (NASDAQ VRAY)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  38 (Vote Outperform)
Underperform Votes:  19 (Vote Underperform)
Total Votes:  57
MarketBeat's community ratings are surveys of what our community members think about ViewRay and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ViewRay (NASDAQ:VRAY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.50 (83.75% upside)

Analysts' Ratings History for ViewRay (NASDAQ:VRAY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/22/2017AegisReiterated RatingBuy$11.00HighView Rating Details
6/29/2017Cantor FitzgeraldInitiated CoverageOverweight -> Overweight$10.00LowView Rating Details
5/17/2017BTIG ResearchReiterated RatingBuy$10.00MediumView Rating Details
5/16/2017Northland SecuritiesReiterated RatingBuy$7.00HighView Rating Details
(Data available from 7/24/2015 forward)


Earnings History for ViewRay (NASDAQ:VRAY)
Earnings by Quarter for ViewRay (NASDAQ:VRAY)
Earnings History by Quarter for ViewRay (NASDAQ VRAY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2017Q1 2017($0.22)($0.24)$0.52 million$1.23 millionViewN/AView Earnings Details
11/14/2016Q316($0.27)($0.35)$0.39 million$0.36 millionViewN/AView Earnings Details
8/15/2016Q216($0.29)($0.32)$5.53 million$0.30 millionViewListenView Earnings Details
5/13/2016Q116($0.30)($0.35)$5.50 million$5.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ViewRay (NASDAQ:VRAY)
2017 EPS Consensus Estimate: ($0.59)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.22)($0.22)($0.22)
Q2 20171($0.24)($0.24)($0.24)
Q3 20171($0.15)($0.15)($0.15)
Q4 20171$0.02$0.02$0.02
(Data provided by Zacks Investment Research)


Dividend History for ViewRay (NASDAQ:VRAY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for ViewRay (NASDAQ:VRAY)
Insider Ownership Percentage: 62.81%
Institutional Ownership Percentage: 49.29%
Insider Trades by Quarter for ViewRay (NASDAQ:VRAY)
Institutional Ownership by Quarter for ViewRay (NASDAQ:VRAY)
Insider Trades by Quarter for ViewRay (NASDAQ:VRAY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/25/2017Fmr LlcInsiderSell106,781$6.76$721,839.56View SEC Filing  
4/24/2017Fmr LlcInsiderSell101,139$6.71$678,642.69View SEC Filing  
4/20/2017Fmr LlcInsiderSell101,236$6.90$698,528.40View SEC Filing  
4/18/2017Fmr LlcInsiderSell107,217$7.24$776,251.08View SEC Filing  
4/13/2017Fmr LlcInsiderSell115,860$7.44$861,998.40View SEC Filing  
4/12/2017Fmr LlcInsiderSell179,494$7.40$1,328,255.60View SEC Filing  
4/10/2017Fmr LlcInsiderSell178,556$7.77$1,387,380.12View SEC Filing  
4/7/2017Fmr LlcInsiderSell52,050$7.89$410,674.50View SEC Filing  
4/5/2017Fmr LlcInsiderSell196,397$7.90$1,551,536.30View SEC Filing  
4/3/2017Fmr LlcInsiderSell217,883$8.29$1,806,250.07View SEC Filing  
3/30/2017Fmr LlcInsiderSell28,661$8.46$242,472.06View SEC Filing  
1/18/2017Ajay BansalCFOBuy62,597$3.17$198,432.49View SEC Filing  
1/18/2017Henry A. MckinnellDirectorBuy312,989$3.17$992,175.13View SEC Filing  
9/9/2016Aditya PuriDirectorBuy1,472,803$2.95$4,344,768.85View SEC Filing  
8/22/2016David P BonitaDirectorBuy1,138,074$2.95$3,357,318.30View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for ViewRay (NASDAQ:VRAY)
Latest Headlines for ViewRay (NASDAQ:VRAY)
DateHeadline logoViewRay, Inc. (NASDAQ:VRAY) Earns "Buy" Rating from Aegis - July 22 at 12:57 PM logoLeading Medical Physics Meeting to Feature First Presentations on Clinical Experience with ViewRay's MRIdian Linac - July 22 at 10:22 AM logoHere's Why ViewRay Inc. Stock Isn't Looking Too Good Today - July 22 at 10:22 AM logoEQUITY ALERT: Rosen Law Firm Announces Investigation of ... - Business Wire (press release) - July 21 at 8:30 AM logoAegis Capital Assumes ViewRay Inc. (VRAY) at Buy - - July 21 at 8:30 AM logoFirst Patients Treated with ViewRay's MRIdian Linac System at Henry Ford Health System - July 21 at 8:30 AM logoEQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against ViewRay, Inc. – VRAY - July 21 at 8:30 AM logoViewRay, Inc. – Value Analysis (NASDAQ:VRAY) : July 12, 2017 - July 12 at 8:21 PM logoETFs with exposure to ViewRay, Inc. : July 11, 2017 - July 12 at 9:01 AM logoViewRay, Inc. breached its 50 day moving average in a Bullish Manner : VRAY-US : July 11, 2017 - July 11 at 9:17 AM logoViewRay, Inc. (VRAY) Expected to Announce Quarterly Sales of $2.58 Million - July 7 at 11:58 AM logoViewRay, Inc. Expected to Earn FY2017 Earnings of ($0.94) Per Share (NASDAQ:VRAY) - July 6 at 8:45 AM logoZacks: Brokerages Expect ViewRay, Inc. (NASDAQ:VRAY) Will Announce Earnings of -$0.25 Per Share - July 5 at 6:34 PM logoCantor Fitzgerald Starts ViewRay Inc. (VRAY) at Overweight - - June 30 at 1:23 AM logoViewRay, Inc. (VRAY) Receives Average Rating of "Buy" from Analysts - June 29 at 6:40 PM logoViewRay, Inc. (VRAY) Receives New Coverage from Analysts at Cantor Fitzgerald - June 29 at 6:02 PM logoETFs with exposure to ViewRay, Inc. : June 26, 2017 - June 26 at 11:52 PM logoViewRay (VRAY) Announces National Cancer Center Japan Treats First Patients Using MRIdian System - - June 26 at 3:32 PM logoNational Cancer Center Japan Treats First Patients Using ViewRay MRIdian System - June 26 at 3:32 PM logoViewRay, Inc. (VRAY) - June 25 at 10:47 PM logoViewRay, Inc. breached its 50 day moving average in a Bullish Manner : VRAY-US : June 23, 2017 - June 24 at 7:46 AM logoETFs with exposure to ViewRay, Inc. : June 16, 2017 - June 17 at 7:08 AM logoViewRay® to Present at The JMP Securities Life Sciences Conference - June 13 at 9:08 AM logoShort Interest in ViewRay, Inc. (VRAY) Rises By 39.1% - June 13 at 7:14 AM logoViewray Inc (VRAY) Expected to Post Quarterly Sales of $2.58 Million - June 11 at 8:30 AM logo-$0.25 EPS Expected for Viewray Inc (VRAY) This Quarter - June 9 at 6:44 PM logoViewRay Powers Up - Our Top Pick For Balance Of 2017 - June 8 at 1:54 AM logoETFs with exposure to ViewRay, Inc. : June 5, 2017 - June 6 at 1:51 AM logoViewRay, Inc. :VRAY-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 - June 3 at 2:05 AM logoViewray Inc (VRAY) Upgraded to "Hold" by ValuEngine - June 2 at 8:04 PM logoViewRay® to Present at Citi's 2017 Small & Mid Cap Conference - May 30 at 8:07 PM logoShort Interest in Viewray Inc (VRAY) Grows By 50.3% - May 28 at 7:10 AM logoResearch Reports Coverage on Medical Equipment Stocks -- Avinger, ViewRay, Align Technology, and Syneron Medical - May 26 at 8:28 AM logoZacks Investment Research Weighs in on Viewray Inc's Q2 2017 Earnings (VRAY) - May 19 at 7:10 AM logoZacks Investment Research Weighs in on Viewray Inc's Q4 2017 Earnings (VRAY) - May 18 at 12:32 PM logoVRAY: First Quarter 2017 Financial Results. Reiterating Annual Revenue Guidance - May 17 at 10:10 PM logoViewray Inc (VRAY) Earns Buy Rating from BTIG Research - May 17 at 1:32 PM logo$3.03 Million in Sales Expected for Viewray Inc (VRAY) This Quarter - May 17 at 11:40 AM logoHere's Why Things Aren't Looking Good for ViewRay, Inc. Today - May 16 at 11:09 PM logoViewray Inc (VRAY) Receives "Buy" Rating from Northland Securities - May 16 at 4:32 PM logoAegis Reiterates Buy Rating for Viewray Inc (VRAY) - May 16 at 8:30 AM logoViewray Inc (VRAY) Posts Earnings Results - May 15 at 9:20 PM logoCompelling Early Pancreatic Cancer Data with ViewRay's MRIdian System Presented at ESTRO 36 - May 15 at 7:42 PM logoInvestor Network: ViewRay, Inc. to Host Earnings Call - May 15 at 7:42 PM logoViewRay Reports First Quarter 2017 Financial Results - May 15 at 7:42 PM logoViewRay reports 1Q loss - May 15 at 7:42 PM logo-$0.23 EPS Expected for Viewray Inc (VRAY) This Quarter - May 15 at 11:44 AM logoViewray Inc (VRAY) Downgraded by ValuEngine to Sell - May 11 at 3:32 PM logoViewRay Announces Conference Call and Webcast of First Quarter 2017 - May 10 at 9:57 AM logoViewray Inc (VRAY) Short Interest Update - May 9 at 8:22 PM



ViewRay (VRAY) Chart for Monday, July, 24, 2017

This page was last updated on 7/24/2017 by Staff